Deliver Biosciences
Nanoparticle-based vectors for in-vivo cell therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Grant | ||
| Total Funding | 000k | ||
Related Content
Founded in 2019, Deliver Biosciences is a preclinical biotechnology company developing a nanoparticle-based delivery platform for genetically engineering cells directly within the patient's body. The company, formerly known as ImmTune Therapies, was co-founded by CEO Dr. Bakul Gupta and CSO Dr. George Tetley. Dr. Gupta's background in biomaterials and chemistry formed the foundation of the company's technology, while Dr. Tetley brings expertise in immunology, biochemistry, and cancer drug discovery.
Deliver Biosciences aims to create affordable, scalable, and potent cell and gene therapies. The company's core technology utilizes customizable nanoparticle vectors to transport diverse payloads like DNA and mRNA to specific cells, avoiding accumulation in off-target organs. This in-vivo approach is designed to circumvent the complex and costly manufacturing processes associated with traditional ex-vivo cell therapies, which can cost upwards of $500,000 per dose. By reprogramming cells inside the body, the company intends to drastically reduce treatment time and cost.
The firm's initial product focuses on cancer immunotherapy, specifically targeting T-cells to deliver a chimeric antigen receptor (CAR) gene, transforming them into tumor-killing CAR-T cells directly within the patient. Beyond oncology, Deliver Biosciences envisions long-term applications for its platform in treating autoimmune diseases like diabetes and arthritis, as well as neurodegenerative and cardiovascular diseases. The business model appears to be centered on proprietary drug development and strategic partnerships with companies and institutions to accelerate clinical development. The company has received funding from entities including Innovate UK, Deep Science Ventures, and SciFounders.
Keywords: nanoparticle delivery, in-vivo cell therapy, gene therapy, CAR-T, drug delivery, cellular reprogramming, biotechnology, cancer immunotherapy, genetic engineering, nanomedicine, DNA delivery, mRNA delivery, targeted therapy, preclinical biotech, life sciences, oncology, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, cell engineering